Both kanamycin A and kanamycin B, antibiotic components produced by Streptomyces kanamyceticus, have medical value. Two different pathways for kanamycin biosynthesis have been reported by two research groups. In this study, to obtain an optimal kanamycin A-producing strain and a kanamycin B-high-yield strain, we first examined the native kanamycin biosynthetic pathway in vivo. Based on the prop...

A kanamycin-producing strain, Streptomyces kanamyceticus ISP5500, is resistant to kanamycin. A kanamycin resistance determinant was cloned from S. kanamyceticus into Streptomyces lividans 1326, using the plasmid vector pIJ702. The resulting plasmid, pMCP5, could also transform Streptomyces lavendulae S985 and Streptomyces parvulus 2283 to kanamycin resistance. Transformants carrying pMCP5 were ...

Two enzymes which phosphorylate neomycin and kanamycin have been detected in Escherichia coli strains carrying R factors. Neomycin-kanamycin phosphotransferase I can phosphorylate neomycin and kanamycin, but not butirosin. Neomycin-kanamycin phosphotransferase II can phosphorylate all three antibiotics. The enzymes also differ in their response to certain inhibitors of phosphorylation. Neomycin...

Kanamycin belongs to the aminoglycoside class of bacteriostatic antibiotics that inhibits protein synthesis. Previous studies have shown that treatment with sublethal levels of kanamycin causes the extracellular polysaccharide capsule in E. coli B23 to increase in size, and potentially confers the bacterium with kanamycin resistance. This study attempted to confirm this by establishing that inc...

Overuse of antibiotics has caused serious problems, such as appearance of super bacteria, whose accumulation in the human body through the food chain is a concern. Kanamycin is a common antibiotic used to treat diverse infections; however, residual kanamycin can cause many side effects in humans. Thus, development of an ultra-sensitive, precise, and simple detection system for residual kanamyci...